De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation
NCT ID: NCT02056054
Last Updated: 2021-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
157 participants
OBSERVATIONAL
2013-09-09
2019-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 1: To conduct a refined phenotypical and functional analysis of regulatory T cells in study and control patient groups.
Rationale: We would like to extend our preliminary data observations in a larger patient group and use this extended data set to conduct a refined phenotypical and functional analysis of regulatory T cells in order to explore if the regulatory T cell phenotype and function in d-AIH differs: (A) from that in controls defined as (i) non-transplanted patients with autoimmune hepatitis (AIH), (ii) LT recipients with acute rejection, (iii) LT recipients with chronic rejection, (iv) non-transplanted patients with chronic hepatitis C; (B) according to the disease etiology leading to transplantation; (C) according to immunosuppressive regimen prior to diagnosis of d-AIH being made and (D) over time during the disease course. This could potentially give us some insight into the causes for immune tolerance breakdown in d-AIH.
Aim 2: To investigate how over expression of IL-17A and HDAC9 genes relates to the regulatory T cell defect observed in liver transplant recipients with d-AIH.
Rationale: Histone/protein deacetylases regulate chromatin remodeling, gene expression and the functions of many transcription factors. Acetylation of histones leads to an open chromatin structure permissive for the initiation of gene transcription and expression. Histone deacetylase inhibition by Trichostatin-A (TSA) has been demonstrated to prevent the production of IL-17A and sustain Foxp3 expression in human T-regs. Importantly, if differentiation of T-regs into a Th17-like phenotype can be inhibited by TSA in d-AIH, this might be of interest for the development of new therapeutic modalities.
We would like to first of all confirm our preliminary data observations in a larger patient population and address any concerns about RNA integrity in formalin fixed paraffin embedded tissue by using fresh liver biopsy tissue to assess the expression of genes involved in T-cell anergy and immune tolerance in LT recipients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects with d-AIH
Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
Pediatric transplant subject with d-AIH
30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Subjects with Acute Rejection
Pediatric transplant patients with acute rejection will be enrolled at an outside center.
Pediatric transplant subject with acute rejection
Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
Subjects with Chronic Rejection
Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
Pediatric transplant subject with chronic rejection
Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
Control Subjects
Healthy pediatric patients will be enrolled at the coordinating center (Yale).
Pediatric control subjects
2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
Subjects with Auto-immune Hepatitis
Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
Adult non-transplant patients with auto-immune hepatitis
75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.
The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
Subjects with Chronic Hepatitis C Virus
Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
Adult non-transplant subjects with chronic hepatitis C virus
For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
Adult Subjects with d-AIH
Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
Adult transplanted subjects with de novo autoimmune hepatitis
75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pediatric transplant subject with d-AIH
30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Pediatric transplant subject with acute rejection
Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
Pediatric transplant subject with chronic rejection
Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
Adult non-transplant patients with auto-immune hepatitis
75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.
The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
Adult non-transplant subjects with chronic hepatitis C virus
For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
Pediatric control subjects
2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
Adult transplanted subjects with de novo autoimmune hepatitis
75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Is \>3-months and \<21 years of age and a recipient of a single organ liver transplant
* Has allograft dysfunction (an ALT and/or GGTP \> 2 times the upper limit of normal) due to acute rejection without a prior diagnosis of d-AIH
* Has allograft dysfunction (an ALT and/or GGT \> 2 times the upper limit of normal) due to chronic rejection without a prior diagnosis of d-AIH
* Has a diagnosis of d-AIH
Healthy Pediatric Control Subjects (Enrolled at Yale)
* Is ≥ 1-year and \< 18-years of age
* Not on any immune modulators
* Not on steroid therapy
* Has no underlying chronic inflammatory condition
Adult Control Subjects (Enrolled at Yale) Non-transplanted Adult patients with autoimmune hepatitis and chronic hepatitis C will also be enrolled.
* Non-transplanted adults "18 Years or \> " with Autoimmune Hepatitis
* Non-transplanted adults "18 Years or \> " with chronic hepatitis C who are treatment naive.
Exclusion Criteria
Healthy Pediatric Control Subjects (Enrolled at Yale)
* \<1-year and \> 18-years of age
* Has chronic inflammatory condition
* On immune modulators or steroids
* On chronic medication(s)
Adult transplanted patients with d-AIH (enrolled at Yale)
\- Transplanted Adults ≥21-years of age with a diagnosis of d-AIH
3 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Udeme Ekong, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Yale University
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1302011561
Identifier Type: -
Identifier Source: org_study_id